bit.bio opens industrial-scale CRISPR screening in human iPSC-derived cells

bit.bio has launched ioScreen, a contract CRISPR-screening service built around human stem-cell-derived models. Pharmaceutical, biotechnology and computational drug-discovery teams can use the company's CRISPR-ready ioCells, other cells from its portfolio or, where suitable, bring their own model into the workflow.

The company is positioning the service for target identification and validation, pathway analysis, mechanistic studies and disease modelling. The launch was accompanied by the appointment of Sejla Salic-Hainzl as bit.bio's first chief technology officer.

The technological angle

Large functional-genomics screens require many consistent cells, specialist perturbation workflows and careful quality control. Those requirements become harder when a project moves from easily expanded immortalised lines into differentiated human cells.

bit.bio says ioScreen combines its deterministic opti-ox programming approach with billions of consistent, mature iPSC-derived cells. Turning that capability into a service matters because it lets teams test gene function in a more relevant cell context without first creating an internal cell-production and screening operation.

The platform may also be useful to developers of computational or “virtual cell” models: perturbation data generated in defined human cell types could provide a more relevant training or validation layer than conventional cancer-derived cell lines.

Why it matters

For new approach methodologies, scale and reproducibility are as important as biological sophistication. A human model that cannot support a sufficiently powered screen has limited value in early discovery. ioScreen is therefore less about a new cell identity than about making iPSC biology operational at screening scale.

What to watch

The announcement describes capabilities rather than publishing comparative performance data. Independent users will want to see screen quality, differentiation consistency, genotype coverage and reproducibility across cell types and customer programmes.

This HCMX news brief is an independent summary of a company announcement published on 13 August 2026.